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Summary 
CTLA-4 is a CD28 homologue beheved to be a negative regulator of T  cell function. How- 
ever, the mechanism of this downregulatory activity is not well understood. The present study 
was designed to examine the effect of CTLA-4 ligation on cytokine production, cell survival, and 
cell cycle progression. The results demonstrate that the primary effect of CTLA-4 ligation is 
not the induction ofapoptosis. Instead, CTLA-4 signaling blocks IL-2 production, IL-2 receptor 
expression, and cell cycle progression of activated T  cells. Moreover, the effect of CTLA-4 sig- 
naling was manifested after initial T  cell activation. Inhibition oflL-2 receptor expression and cell 
cycle progression was more pronounced at late (72 h) time points after initial activation. The 
effects of anti-CTLA-4 mAbs were most apparent in the presence of optimal CD28-medi- 
ated costimulation consistent with the finding that CTLA-4 upregulation was CD28-depen- 
dent. Finally, the addition of exogenous IL-2 to the cultures restored IL-2 receptor expression 
and T  cell prohferation. These results suggest that CTLA-4 signaling does not regulate cell sur- 
vival or responsiveness to IL-2, but does inhibit CD28-dependent IL-2 production. 
C 
D28/B7  interactions play a central role in providing 
costimulatory signals to T  cells. Ligation of CD28 by 
B7-1  and/or B7-2  has  been  shown  to  induce  T  cells  to 
regulate growth factor (IL-2) production (1,  2),  T  helper 
cell differentiation (3,  4),  and programmed cell death (5). 
Over 8 yr ago, a structural homologue of CD28, CTLA-4, 
was discovered among a set of T  cell-specific, activation- 
induced genes (6).  Not only was CTLA-4 found to share 
structural homology with CD28, but it also shares the abil- 
ity to bind B7-1  and B7-2  (7,  8).  Further studies demon- 
strated that the CTLA-4 glycoprotein is expressed on the 
surface of activated CD4 + and CD8 + T  cells (9-11) and on 
activated B  cells  (12).  Whereas CD28 is constitutively ex- 
pressed on resting human and murine T cells (13), CTLA-4 
is upregulated after T  cell activation, with peak expression 
between 48-72 h  (9, 10). Initial studies have also suggested 
that CTLA-4 upregulation is CD28-dependent. First,  anti- 
CD28 mAbs accelerate the kinetics ofCTLA-4 mRNA ac- 
cumulation  in  human  PBL  (14).  Second,  the  degree  of 
CTLA-4 upregulation was significantly reduced on T  cells 
from CD28-deficient mice (10). 
Early findings suggested that CTLA-4 hgation on acti- 
vated T  cells provided additional costimulatory signals  (9). 
However, recent studies in vitro (10,  11) and in vivo (15) 
have suggested that rather than acting to costimulate T  cells, 
CTLA-4 may actually be involved in the downregulation 
of T  cell responses, perhaps as an antagonist of CD28 co- 
stimulation. Monovalent Fab fragments of an anti-murine 
CTLA-4 mAb, which prevent the interaction of CTLA-4 
with its  counter-receptors, augment prohferation of purl- 
fled T  cells by interrupting the transduction of a negative 
signal  (10).  In  contrast,  whole  anti-CTLA-4  mAbs,  that 
could cross-link  CTLA-4, inhibited T  cell proliferation when 
the T  cells were activated by anti-CD3 in the presence of 
optimal  CD28  costimulation.  Monovalent  Fab  fragments 
of the antibody, that cannot cross-link CTLA-4, had no ef- 
fect in this system (t0). In addition to the in vitro and in 
vivo data using mAbs,  there is now direct evidence for a 
physiologic role for CTLA-4 in the downregulation of acti- 
vated T cells. CTLA-4-deficient mice manifest a massive lym- 
phoproliferative disorder, increased numbers of activated T 
cells and autoimmune-like tissue destruction (16,  17). These 
data are consistent with an integral role for CTLA-4 signal- 
ing in the negative regulation of activated T  cells. 
Although there is  now ample  evidence to suggest that 
CTLA-4 is involved in the downregulation of activated T 
cells, the mechanism remains unclear. Two possibilities seem 
plausible.  First, CTLA-4 hgation may inhibit T  cell function 
by inducing apoptosis in activated T cells. In support of this 
possibility, Gribben et al.  (18) have shown that incubation 
of preactivated human T  cells with antigen in the presence 
of an anti-CTLA-4 mAb induces apoptosis. Second, CTLA-4 
may inhibit  T  cell activation by preventing early or late 
events in T  cell activation,, such as gene expression, growth 
factor production, and/or cell cycle progression. If CTLA-4 
is a CD28 antagonist, it is possible that it may function, in 
particular,  to  regulate  IL-2  production,  a  growth  factor 
known to be induced by CD28 hgation and to be impor- 
tant for cell cycle progression and T  cell expansion. 
In  the present study,  anti-CTLA-4 mAb were used to 
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CTLA-4  expression as  well  as  the  mechanism by  which 
CTLA-4 inhibits T  cell activation. The results demonstrate 
that  CTLA-4 expression on naive T  cells is  regulated by 
costimulation through  CD28/B7-2  interactions. In  addi- 
tion, antibodies to CTLA-4 inhibit anti-CD3/anti-CD28- 
induced  T  cell  proliferative  responses  by  blocking  IL-2 
production, sustained IL-2 receptor expression and events 
that  regulate  progression  of the  cells  into  the  cell  cycle. 
CTLA-4 does not seem to regulate programmed cell death. 
Materials  and Methods 
Animals.  4--8-wk-old C57BL/6 (B6) mice were purchased from 
Frederick National Cancer Institute (Bethesda, MD). 4--8-wk-old 
2C TCR transgenic  (2C) 1 mice were derived as previously de- 
scribed  (19), bred, and maintained under specific-pathogen free 
conditions in the University of Chicago Animal Barrier  Facility. 
2C  ￿  Ipr/Ipr [2C(lpr)] mice were generated by breeding 2C ani- 
mals to B6.1pr/Ipr  (purchased  from the Jackson Laboratory,  Bar 
Harbor, ME).  F1 mice were screened for the 2C transgenes with 
the anti-clonotypic mAb,  1B2  (20) and 2C Tg  + F1  mice were 
bred back to B6.1pr/lpr.  Offspring  of this mating were screened 
for the 2C transgenes as described above and for the Ipr mutation 
by polymerase  chain reaction (PCR)  of tail DNA as  described 
elsewhere  (21). 2C(Ipr)  mice were used at 3-5 wk of age. 
Cell Lines and Reagents.  UC10-4F10-11 (hamster anti-murine 
CTLA-4 [10]), 145-2Cll (hamster anti-murine CD3 [22]), 2.4G2 
(rat anti-mouse FcR [23]), 1B2 (mouse anti-2C TCR [20]), J11d 
(rat anti-murine HSA  [24]), GL-1  (rat anti-murine B7-2  [25]), 
AT83A (rat anti-Thyl.2 [26]), and the 25-9-3 (mouse  anti-I-A  b 
[27]) were prepared in our laboratory.  PV-1  (hamster anti-murine 
CD28 [28]) was kindly provided by Dr.  Carl June (Naval Medical 
Research Institute, Bethesda, MD). Purified hamster Ig (purchased 
from Cappel Research Products,  Durham, NC) was used as neg- 
ative control hamster antibodies in in vitro cultures.  Control hu- 
man Ig, human CTLA4Ig, 16-10A1  (hamster  anti-murine B7-1 
[29]) and Fab fragments of the anti-CD28 n~Ab  were provided by 
the  Repligeu  Corporation  (Cambridge,  MA).  The  coding se- 
quence  for  the  extracellular  portion  of human  CTLA-4  was 
joined to the hinge-CH2-CH3 domains derived from a human 
genomic IgG1 gene by PCR  as previously described  (30). Fab 
fragments of the anti-CTLA-4 mAb, UC10-4F10-11 were gen- 
erated  in  our  laboratory  as  previously  described  (10). Anti- 
CTLA-4 Fab fragments were tested in comparison to whole anti- 
CTLA-4 mAb for their ability to competitively inhibit binding  of 
FITC-conjugated UC10-4F10-11 to CTLA-4 transfected  CHO 
cells (10). The Fab fragments inhibited binding  of the FITC-conju- 
gated anti-CTLA-4 "~10-fold less well than whole anti-CTLA-4. 
However,  multiple studies  both in vitro  (10) and in vivo (15) 
have shown that the doses of Fab used in the present studies are 
sufficient  to  mediate  biological effects. Rat  anti-murine CD8 
(2.43  [31]) and hamster anti-murine CTLA-4 (UC10-4F10-11 
[10]) coupled to FITC were prepared in our laboratory.  Biotiny- 
lated  anti-IL-2R (7D4)  was  purchased  from  PharMingen (San 
Diego,  CA).  HTC-conjugated anti-CD3 (145-2Cll)was pro- 
vided by Boehringer Mannheim (Indianapolis, IN).  Phycoeryth- 
1Abbreviations used in this paper: 2C, 2C TCR transgenic;  t36, C5713L/6; 
control Ig, control hamster immunoglobulin; FcR, Fc receptor; PCD, 
programmed cell death; Tg, transgenic;  TUNEL, terminal deoxynucleo- 
tidyl transferase dUTP nick end labeling. 
fin-conjugated streptavidin (SAV-PE) was purchased  from South- 
ern Biotech (Birmingham, AL). 
Bulk  T  Cell Activation  Cultures  to Examine  CTLA-4  Induction. 
Spleens were harvested  from B6 mice and depleted of erythro- 
cytes with ammonium chloride-potassium  lysing buffer.  Spleno- 
cytes were  cultured alone in DMEM  containing 10% fetal calf 
serum or in the presence  of 10 lag/ml soluble anti-CD3. To ex- 
amine the role of CD28 in the regulation of CTLA-4 expression, 
Fab  fragments  of anti-CD28,  CTLA~Ig,  anti-B7-1,  anti-B7-2, 
control human Ig or control hamster Ig were added at 100 I~g/ml 
final concentration. Cells were examined for CTLA-4 expression 
by flow cytometry at 48 h after the initiation of culture. 
Flow Cytometric Analysis.  After harvest, cells were washed once 
in FACS  |  buffer  (0.1% BSA and 0.01%  Sodium Azide  in PBS, 
pH 7.4) and simultaneously stained with FITC- and biotin-con- 
jugated mAb as described  for 30 rain at 4~  Cells were washed 
again in FACS  |  buffer and incubated with SAV-PE to develop 
biotinylated mAb for 15 rain at RT. After a final wash in FACS  | 
buffer, cells were analyzed on a FACScan  |  flow cytometer (Bec- 
ton-Dickinson, Mountain View, CA). Incorporation of propid- 
ium iodide was used to exclude dead cells. Data was analyzed us- 
ing both  Lysis  II  (Becton-Dickinson) and  WinMDI  software 
(Joseph Trotter, Salk Institute, available by anonymous ftp offflo- 
sun.salk.edu  in/pub/pc). 
T Cell Proliferation Assays.  2C and 2C(lpr) lymph node cells were 
enriched for T  cells by passage over nylon wool columns. MHC 
Class I1  + cells  were further depleted using a mixture ofanti-HSA 
(Jlld) and anti-I-A  b (25-9-3)  culture supernatants plus rabbit com- 
plement (Pel-Freez,  Brown Deer, WI). T  cell purity was evalu- 
ated by flow cytometry using anti-CD3 mAb. In all cases, T cells 
used  in these  assays were  >97%  CD3 +.  Purified T  cells were 
plated out at 2  X  10S/well in the presence  of I  ￿  105 irradiated 
(2,000 rads) syngeneic, erythrocyte-depleted B6 splenocytes. Syn- 
geneic feeder  cells were depleted of T  cells by incubation with 
anti-Thy 1.2 and rabbit complement. Anti-CD3 (0.1 Ixg/ml), anti- 
CD28 (1 p~g/ml), anti-CTLA-4 (50 Ixg/ml), control hamster IgG 
(50 p~g/ml), anti-CTLA-4 Fab fragments (50 p,g/nil), and recom- 
binant human 1L-2 (rlL-2)  (50 U/nil) were used as described  in 
the results section.  Assays were carried out for 72 h at 37~  and 
were pulsed with 1 IxCi/well [3H]thymidine  (Amersham  Corp., 
Arlington Heights,  IL)  for the last  16  h  of culture. Counts are 
represented as the mean of triplicate  wells with standard  errors 
<10%.  All  experiments were  carried  out a  minimum of three 
times with similar results. 
IL-2 Determination.  Superuatants from duplicate cultures of the 
above described  proliferation assays were harvested  at 24 h after 
initiation of culture and stored  at  -20~  until assayed using a 
commercial IL-2 ELISA kit from Endogen (Cambridge, MA). A 
murine IL-2 standard was used to quantify IL-2 levels in the su- 
pernatants (represented  as pg/ml). 
Terminal Deoxynucleotidyl  Transferase (Tdt)-mediated  dUTP Nick 
End Labeling (TUNEL) Assay  for Apoptosis.  Cells  were  harvested 
72  h  after  the initiation of culture and washed  once in FACS  | 
buffer.  Harvested  cells were fixed  overnight at 4~  in 1% para- 
formaldehyde.  Cells were then washed twice in PBS before incu- 
bation in Tdt buffer  containing 2.5  mM CoC12 (as supplied  by 
Boehringer Mannheim (Indianapolis, IN). DNA degradation  was 
determined by the level of incorporation of BODIPY-conjugated 
dUTP (Molecular Probes,  Eugene, OR) when Tdt enzyme was 
added to the fixed  cells. Suspended cells were incubated in the 
dark for 30 rain in a 37~  water bath, with or without Tdt, washed 
once in 15 mM EDTA, once in 0.1% Triton-X 100, and finally 
suspended  in PBS.  Cells were analyzed for BODIPY-dUTP in- 
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rescence data were collected on 5 ￿  103 cells. 
Cell Cycle Analysis.  Cultured  cells were  passed  over  Ficoll- 
Hypaque to remove dead cells. The live  cells were stained  with 
anti-CD8-FITC in FACS  |  buffer, washed in PBS and fixed in 
0.25%  paraformaldehyde for 15 min at room temperature.  Cells 
were washed once in PBS, fixed with 70% methanol and stored 
overnight at  -20~  After 2 washes  in PBS,  cells were  treated 
with IkNase at 10 p~g/ml at 37~  for 30 min. Cells were washed 
once in PBS and resuspended in PBS containing 10 ~g/ml pro- 
pidium iodide.  Logarithmically amplified  fluorescence data  was 
collected on 104 cells. 
Results 
Anti-CTLA-4  mAb Ig But Not Fab Fragments Inhibit  T  Cell 
Proliferative Responses.  As  described  previously  (10),  anti- 
CTLA-4 mAb, when cultured in the presence of anti-CD3 
mAb and optimal costimulation via an anti-CD28 mAb, in- 
hibited T  cell proliferation.  This inhibition of proliferation 
required  Fclk cross-linking  of the  anti-CTLA-4 mAb be- 
cause Fab fragments of  the anti-CTLA-4 mAb had no effect 
on proliferation in this system (Fig.  1 A). The Fab fragments 
have previously been shown to effectively bind CTLA-4 and 
modulate immune responses both in vitro (10) and in vivo 
(15). Similar results were observed upon stimulation of 2C 
TC1K Tg lymph node cells with alloantigen or the bacterial 
superantigen staphylococcal enterotoxin B  (data not shown). 
It is unlikely that the anti-CTLA-4 mAb blocked prolifera- 
tion by competing for Fclk-mediated  cross-linking  of the 
anti-CD3  or anti-CD28 mAbs since the anfi-CTLA-4 mAb 
did not inhibit anti-CD3-mediated  T  cell activation  (Fig.  1 
B).  In fact, in multiple  experiments  (Fig.  1 B  and reference 
10), anti-CTLA-4 mAbs siguificantly enhance proliferative 
responses in  the absence  of maximal CD28  costimulation. 
Finally, these results have been confirmed and extended by 
studies of other investigators using anti-CTLA-4 mAbs di- 
rectly  immobilized  on  plastic  beads  with  anti-CD3  and 
anti-CD28 mAbs (11). 
CD28 Signaling Regulates CTLA-4  Upregulation.  Optimal 
CD28 costimulation was essential  for the anti-CTLA-4 mAbs 
to manifest their inhibitory activity. These results suggested 
that  CTLA-4  expression  and/or  signaling  was  dependent 
on CD28  engagement.  Previous studies  using CD28-defi- 
cient mice have suggested that CD28 costimulation was es- 
sential  for  maximal  upregulation  of CTLA-4  expression 
(10).  To  directly  examine  the  role  of CD28/B7  interac- 
tions in CTLA-4 upregulation, whole B6 spleen cells were 
stimulated  with  anti-CD3  in  the  presence  of anti-CD28 
Fab  fragments  or  CTLA4Ig.  As  seen  in  Fig.  2  (A)  both 
CD28  antagonists  inhibited  the  upregulation  of CTLA-4 
on  the  CD8 +  T  cells.  Interestingly,  the  addition  of anti- 
B7-2, not anti-B7-1, inhibited CTLA-4 expression (Fig. 2/3) 
consistent with previous findings suggesting a primary role 
of B7-2 in CD28-mediated T  cell costimulation. Thus, op- 
timal CTLA-4 expression is dependent on costimulation of 
T  cells  through  the  CD28  receptor.  In fact,  the  require- 
ment for CD28 signals to upregulate CTLA-4 expression after 
T  cell  activation may explain,  in part,  why the inhibitory 
effects of the anti-CTLA-4 mAb are  only observed in the 
presence of optimal costimulation through CD28 (Fig. 1 B). 
The  enhanced  proliferative  response  observed  in  the  ab- 
sence of anti-CD28  costimulation may reflect an ability of 
even small levels  of high  affinity CTLA-4 to  compete for 
B7 binding by CD28. 
Inhibition  of Proliferation by Anti-CTLA-4  in the Presence of 
Anti-CD28 Is Not Fas-dependent.  Previous studies using hu- 
man T  cells have suggested that the engagement of CTLA-4 
inhibits T  cell proliferation by inducing apoptosis of the ac- 
tivated T  cells  (18).  Fas-mediated cell death has been pro- 
posed to be a  major pathway for regulating cell expansion 
after  TC1K ligation  in  several model  systems  (32).  There- 
fore, the role of Fas in anti-CTLA-4-mediated suppression 
of proliferation  was  directly examined  using the  Fas-defi- 
cient  Ipr mouse  (33,  34).  2C mice ~vere bred to B6.1pr/Ipr 
[2C(Ipr)]. Tg  §  T  cells from these animals, which produce a 
defective  Fas  protein  that  is  unable  to  transduce  an  apop- 
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Figure 1.  Anti-CTLA-4 inhi- 
bition of 2C T cell proliferation 
is  CD28-dependent. Two-hun- 
dred thousand purified 2C TCR, 
Tg  + T cells were cukured with 
1  X  105  syngeneic, irradiated 
T-depleted  splenocytes  in  the 
presence  of  both  suboptimal 
TCR  stimulation  (0.1 p,g/ml 
anti-CD3) and optimal co-stim- 
ulation (1.0 Ixg/ml anti-CD28) 
(A)  or in  the presence of anti- 
CD3 stimulation alone (B). Con- 
trol  Ig,  anti-CTLA-4 or  anti- 
CTLA-4  Fab  fragments  were 
added  at  50  ~g/ml.  The  assay 
was harvested at 72 h after a 16-h 
pulse with  1 ~Ci/well  [3H]thy- 
midine. Figure  2.  Co-stimulation  through  CD28  regulates CTLA-4  expres- 
sion. CTLA-4 upregulation was examined in the presence of Fab frag- 
ments of anti-CD28 mAb, CTLA4Ig, anti-B7-1 or anti-BT-2 mAb. B6 
splenocytes were cultured in the presence ofanti-CD3 and 100 ~g/ml of 
the indicated antagonist or control Ig for 48 h. CTLA-4 expression was 
examined on the CD8 + T cells by two-color flow cytometry. Data repre- 
sents the  mean fluorescence intensity of anti-CTLA-4  staining on the 
CD8 + T cell population. 
totic signal, were analyzed for their ability to proliferate in re- 
sponse to anti-CD3  and  anti-CD28  in  the presence/absence 
of  anti-CTLA-4  mAbs.  The  presence  of  anti-CTLA-4 
mAbs in the  activation  cultures  resulted  in profound  inhi- 
bition  of anti-CD3/anti-CD28-induced  T  cell  prolifera- 
tion  (Fig.  3)  similar to that observed with  control  Fas + 2C 
T  cells (Fig.  1 A). Together,  these results suggested that the 
mechanism of CTLA-4-mediated effects on T  cell prolifer- 
ation was not via a Fas-dependent apoptotic pathway. 
Inhibition of T  Cell Proliferation by Anti-CTLA-4  mAbs Is 
Not Mediated by Apoptosis.  Recent  studies  have  supported 
Fas-independent mechanisms ofapoptosis after TC1K ligation 
(35).  Thus,  a  TUNEL  assay was used  to  examine whether 
the anti-CTLA-4 mAbs induced  DNA  degradation  consis- 
tent with Fas-independent  programmed cell death. As pre- 
viously shown  (5,  10)  T  cells stimulated  with  anti-CD3  in 
the absence of CD28 costimulation exhibit significantly re- 
duced proliferative responses and profound apoptotic death. 
As  seen  in  Fig.  4,  2C  Tg  +  T  cells  proliferated  poorly  to 
anti-CD3  alone  (A)  and  over  40%  of the  cells  were  ob- 
served to be undergoing apoptosis at 72 h  (B). The addition 
of anti-CD28  mAb significantly increased proliferation and 
reduced  the percentage  of cells undergoing  apoptosis  (6.1- 
9.5%)  (Fig.  4  B).  These results are consistent with previous 
studies demonstrating  the cell survival effects of CD28  sig- 
naling  (5).  The  effects of anti-CTLA-4  mAbs were  exam- 
ined in this assay. Although  the proliferation of activated T 
cells was significantly inhibited  by the addition  of the anti- 
CTLA-4 mAbs (Fig. 4 A), the percentage ofapoptotic  cells 
remained comparable to the level observed in control  cul- 
tures  (Fig.  4  B).  These data suggested that downregulation 
of proliferation by CTLA-4 cross-linking was not mediated 
by induction  of apoptosis  in  activated  T  cells.  Moreover, 
the results support previous evidence that the anti-CTLA-4 
mAb does not mediate its suppressive effects by competing 
with anti-CD28 for FclK engagement since blockade of CD28 
signaling would have been expected to promote apoptosis. 
Figure 3.  Anti-CTLA-4-mediated  inhibition  of proliferation is Fas- 
independent. 2C T cell proliferation  assays  were set up as described in Fig. 1. 
Responding T cells were purified from the lymph nodes of 2C (Ipr) mice. 
The results depicted in this figure are representative of three separate ex- 
periments. 
CTLA-4 Suppresses Late, but Not Early, Cell Cyde Progres- 
sion.  The previous results suggested that CTLA-4 regulates 
T  cell proliferation by inhibiting proliferation independently 
of programmed  cell  death  (PCD),  perhaps  by blocking  T 
cells  from  progressing  through  the  cell  cycle.  To  address 
this  issue  directly,  we  examined  the  ability  of anti-CD3/ 
anti-CD28-activated  T  cells  to  progress  through  the  cell 
cycle  in  the  presence  of anti-CTLA-4  mAbs.  As  seen  in 
Fig.  5,  there was no apparent difference in the progression 
ofT cells into the cell cycle at the early (24 h) time point in 
anti-CD3/anti-CD28-stimulated  T  cells  cultured  in  the 
absence or presence of the anti-CTLA-4 mAbs. In contrast, 
there  were  consistently  less  T  cells  (15%)  in  the  S/G2-M 
phase of the cell cycle in the anti-CTLA-4-treated  cultures 
when  compared  to  control  Ig-treated  cultures  at 72  h.  As 
previously noted,  CTLA-4 is upregulated after initial T  cell 
activation.  Therefore,  it  is likely that  the  inhibitory  effect 
of CTLA-4  ligation  is  subsequent  to  the  initiating  signals 
after TCIK ligation  that  are responsible  for driving  T  cells 
into early phases of the cell cycle. 
Signals through CTLA-4 Inhibit Sustained Expression of IL-2 
Receptor (IL-2Ra) and IL-2 Production.  The previous results 
suggested that CTLA-4 acts subsequently to the initial TCR 
signaling  events  to  regulate  T  cell  growth.  Therefore,  we 
examined two events known to be important for sustained 
T  cell growth,  the  expression  of the  low affinity IL-2Ro~ 
chain  and production  of IL-2.  Fig.  6  shows  the kinetics  of 
IL-2Rcx  chain  expression  on  2C  TCR  Tg  +  T  cells  acti- 
vated under  control  conditions  or in  the presence  of anti- 
CTLA-4 mAbs. Although there was no observable effect of 
the  anti-CTLA-4  mAb  on  the level  of IL-2Ro~  chain  ex- 
pression  on  the  surface  of the  activated  T  cells  at  24  h,  a 
marked decrease in IL-21Kcx expression was evident by 48 h 
(data not shown) and 72 h  (Fig.  6). Thus, low affamty IL-2Rcx 
chain expression on activated T  cells is inhibited  by signal- 
ing via CTLA-4. 
The anti-CTLA-4  mAbs appeared to have a preferential 
effect on late  events  in  cell  cycle progression  and  IL-2Re~ 
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eration  by anti-CTLA-4 mAb is 
not  mediated  by  apoptosis. The 
proliferation assay was set up as de- 
scribed in  Fig.  1.  A  depicts  the 
proliferative  response  of 2C  T 
cells subjected to the PCD analy- 
ses. B depicts  the PCD analysis. 
2C  cells were harvested  at 72 h 
after  the  initiation  of  culture. 
Apoptosis  was  measured  as  de- 
scribed in Materials and Methods 
using  the  TUNEL  assay.  The 
amount  of apoptosis  was  deter- 
mined by examining the number of cells that incorporated  the fluorescein-conjugated  dUTP (BODIPY-dUTP) in each sample by flow cytometry.  This 
assay is representative  of three separate experiments. 
expression.  Previous studies have shown that IL-2 is a posi- 
tive regulator of IL-2P,.c~ expression  (36)  and is essential for 
cell cycling,  though  less  is  known  about  the  regulation  of 
functional  high affinity IL-2R.  Therefore  IL-2 production 
by  Tg  §  T  cells  stimulated  with  anti-CD3/anti-CD28  in 
the  presence  of a  control  hamster  IgG  or  anti-CTLA-4 
mAb  was  examined.  Significant  suppression  of IL-2  pro- 
duction  (70%  in  the  experiment  shown  in  Fig.  7)  by  the 
addition  of anti-CTLA-4  mAbs  was  observed  in  repeated 
experiments,  consistent  with  a  direct  role  for  CTLA-4  in 
the  regulation  of IL-2.  In fact,  the  addition  of exogenous 
IL-2 promoted  the  aborted  cell  cycle progression  (Fig.  5), 
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Figure  5.  CTLA-4  ligation  inhibits  cell  cycle 
progression.  Purified  2C T  cells were activated  as 
previously  described  and  harvested  at either 24 or 
72  h.  Cells  were  stained  with  CD8-FITC,  fixed 
and  DNA staining  was performed as described  in 
Materials and  Methods.  The DNA distribution  of 
CD8 + T  cells is depicted  by histograms. The per- 
centage  of cells in S/G 2 was determined  by com- 
parison  of activated  cell populations  with an  un- 
stimulated  control 2C T  cell population.  The top 
left and  right panels represent cells stimulated with 
anti-CD3/anti-CD28 in the presence of control  Ig. 
The  middle  left  and  right  panels  represent  cells 
stimulated  with anti-CD3/anti-CD28 in the pres- 
ence of anti-CTLA-4 mAbs. The bottom left and 
right  panels  represent  cells stimulated  with  anti- 
CD3/anti-CD28  and  anti-CTLA-4  mAb  in  the 
presence of exogenous human recombinant IL-2 (50 
U/ml). 
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Figure 6.  Sustained IL-2 receptor expression is in- 
hibited by anti-CTLA-4  mAb.  Purified  2C T  cells 
were  stimulated  as  previously  described  in  Fig.  1 
with anti-CD3 and  anti-CD28 in the presence  of 
control hamster  Ig (top),  anti-CTLA-4 (middle),  or 
anti-CTLA-4 plus  IL-2  (bottom).  The  2C  T  cells 
were harvested at 24 and 72 h after activation  and 
examined  for IL-2R expression by two-color flow 
cytometry.  The data is represented as histograms for 
IL-2R expression after gating on CD8 + T cells. 
reversed the downregutation  of IL-2Rcx expression  (Fig. 6) 
and  reconstituted  T  cell proliferation  (Fig.  8)  in  the  anti- 
CTLA-4  treated  cultures.  Together these  data  suggest  that 
CTLA-4  acts  to suppress  IL-2 production,  resulting in de- 
creased  IL-2P,.0t  expression,  but  not  IL-2  responsiveness, 
under culture  conditions where there is optimal costimula- 
tion through  CD28. 
Figure 7.  CTLA-4 ligation in the presence of CD28 costimulation  in- 
hibits the production oflL-2. Purified 2C T cells were stimulated with anti- 
CD3 (0.1 ~g/ml) or anti-CD3 and anti-CD28 (1 ~g/ml) in the presence 
of Control Ig, anti-CTLA-4, or anti-CTLA-4 Fab fragments (50 Ixg/ml) 
in the presence ofT cell depleted, syngeneic irradiated feeder cells. Super- 
natants  were  collected  at  24  h  and  tested  for the presence  of IL-2 by 
ELISA. 
Discussion 
The function of CTLA-4,  a cell surface molecule on ac- 
tivated T  cells  (originally identified in  a  mRNA  library  of 
activated CTL), remains controversial. CTLA-4 was shown to 
bind  B7-1/B7-2  and,  based  on  its  sequence  homology  to 
the  CD28  molecule, was  predicted  to  function  as  a  mem- 
ber of the  CD28  class  of costimulatory  molecules.  In fact, 
early studies supported  a  costimulatory role for CTLA-4  in 
promoting T  cell proliferation  (9,  37).  However,  more re- 
2546  CTLA-4 Ligation Blocks IL-2 Production Figure  8.  Inhibition of proliferation by anti-CTLA-4 mAb can be re- 
versed by the addition of exogenous IL-2. Purified 2C T cells were stim- 
ulated with anti-CD3 and anti-CD28 (as described in Fig. 1) in the pres- 
ence of Control Ig,  anti-CTLA-4 mAb  or  anti-CTLA-4 mAb  and 
recombinant human 1L-2 (50 U/ml) (Anti-CTLA-4/IL-2).  Proliferation 
was measured at both 24 and 72 h after the initiation of culture. 
cent  studies  have suggested that  rather  than promoting T 
cell activation, engagement of  CTLA-4 actually inhibits T  cell 
function  (10,  11,  18). First,  we  showed  that  blockade  of 
CTLA-4 engagement with  its  natural ligands by Fab frag- 
ments of anti-CTLA-4 mAbs enhanced T  cell proliferation 
both  in  vitro  and  in  vivo  (10,  15).  In  addition,  we,  and 
others,  developed  an  assay  system  wherein  cross-linking 
CTLA-4  with  mAbs  inhibited  T  ceils  stimulated  through 
CD3  and  CD28  (10,  11).  Finally,  recent  studies  using 
CTLA-4-deficient mice have emphasized the importance of 
the  CTLA-4-mediated  downregulatory  activity.  CTLA-4 
knockout  mice  demonstrate  a  massive lymphoproliferative 
response  (16,  17).  In  the  present  studies,  we  address  the 
mechanism by which CTLA-4 downregulates T  cell func- 
tion.  The data suggest that  CTLA-4 does not mediate its 
effects  through  Fas-mediated  or  other  forms  of  pro- 
grammed cell death.  However,  CTLA-4 cross-linking in- 
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hibits  cell  cycle progression,  sustained  IL-2Rot expression 
and IL-2 production.  Furthermore,  the most profound ef- 
fects  of CTLA-4  cross-linking  occur  in  the  presence  of 
maximal CD28-mediated T  cell costimulation. 
There are several possible models for how CTLA-4 may 
be antagonizing CD28-mediated signals.  It is possible that 
CTLA-4 may inhibit T  cell activation by directly antago- 
nizing initial CD28 signals,  especially since CTLA-4 has a 
higher affinity for B7-1 and B7-2 than does CD28  (7, 38). 
This  "cell  surface  competition"  hypothesis  does  not  fully 
explain the results for two reasons. First,  we have observed 
opposing effects of whole versus Fab fragments of the anti- 
CTLA-4 mAbs. The addition of whole anti-CTLA-4 mAb 
inhibited T  cell activation when anti-CD3 and anti-CD28 
were  present,  while  the  addition  of Fab fragments to  the 
culture had no effect or actually enhanced T  cell prolifera- 
tion. If CTLA-4 was merely competing with CD28 for in- 
teraction with the B7 family members, both Fab fragments 
and whole anti-CTLA-4 mAbs would be expected to aug- 
ment proliferation by blocking CTLA-4 interactions  with 
the counter-receptors, thus making more of the B7-family 
member molecules available for CD28 ligation.  Second,  if 
CTLA-4 was competing with CD28 for B7 ligation,  then 
CD28 signaling would have been expected to be impaired 
on the naive T  cells.  It has previously been shown that the 
blockade of CD28/B7 interactions leads to a rapid decrease 
in  cell  survival  as  a  direct  result  of apoptosis  (5).  The 
present study showed that inhibition of T  cell proliferation 
after CTLA-4 cross-linking was not related to apoptosis, al- 
though  we  cannot  rule  out  that  rapid  apoptosis  of cells 
might not be detected in these cultures.  However, overall 
cell yield over time would not be consistent with this inter- 
pretation of the data. Analyses ofFas-defective T  cells failed 
to  provide any evidence of increased  cell death  among T 
cells  cultured  with  the  anti-CTLA-4  mAb,  nor  did  the 
mAb affect augmentation of cell  survival effected by anti- 
CD28.  Gribben  et  al.  (18)  have  suggested  that  CTLA-4 
may regulate T  cell function by inducing apoptosis of acti- 
vated T  cells,  since, in their study, one anti-CTLA-4 inAb 
was shown to directly mediate apoptosis of human allore- 
active T  cell clones.  There  are  two  important  differences 
that  may  explain  the  differences  between  our  study  and 
those  of Gribben  et  al.  First,  the  anti-CTLA-4 mAb  de- 
scribed  does  not  react  with  the  same  epitope  as  UC10- 
4F10-11.  UC10-4F10-11  inhibits the interaction orB7-1  or 
B7-2 with murine CTLA-4Ig (data not shown). In contrast, 
the  anti-human  CTLA-4  mAb studied  by Gribben  et  al. 
(18)  was  selected  for  its  distinct  binding  to  a  CTLA-4 
epitope unrelated to B7 binding.  In fact, anti-CTLA-4 an- 
tibodies that intereacted with  the 137  binding site did  not 
induce apoptosis in  their system. Second,  our studies used 
primary, naive T  cells as opposed to T  cell clones. Since T 
cell clones are dependent ultimately on IL-2 for survival, it 
is possible that inhibition of IL-2 production by the T  cell 
clones  led  to  the  observed programmed cell  death  in  the 
Gribben et al. study (18). 
The finding that anti-CTLA-4 mAbs appeared to prefer- 
entially affect IL-2 production early following T  cell activa- tion is intriguing. Several early T  cell activation events such 
as entry into cell cycle and initial IL-2R upregulation were 
not altered by CTLA-4 cross-linking. However, IL-2 pro- 
duction was inhibited at the 24-h time point.  Lucas et al. 
recently  reported  similar  results  documenting  that  IL-2 
production,  but not early IL-2R expression, was severely 
impaired in CD28 knockout mice (39).  In addition, Sper- 
ling et al.,  (Sperling, A.I., J.A. Auger, B. Ehst,  I.C. Rulif- 
son, C.B. Thompson, and J.A. Bluestone, manuscript sub- 
mitted for pubhcation) have shown that CD28 signals  may 
not be required  for early T  cell activation events, but are 
necessary for T  cell survival and sustained proliferative re- 
sponses. In fact, it is striking that the most profound inhibi- 
tion of T  cell activation following TCR  cross-linking oc- 
curs  in  the  presence  of  optimal  costimulation  through 
CD28.  These  results  suggest  that  cross-hnking  by  anti- 
CTLA-4  mAbs  selectively inhibits  CD28-dependent  sig- 
naling events. The data also support recent suggestions that 
IL-2 production is not essential to initiate  the transit of T 
cells into the cell cycle, but that the lack of this growth fac- 
tor  may impede  cell  cycle progression,  prevent  sustained 
IL-2R expression and T  cell expansion. 
Thus,  it  will  be  important  to  determine  whether  the 
negative signals delivered by CTLA-4 cross-linking directly 
antagonize signals  through CD28  (such as the activation of 
protein tyrosine kinases) that are essential for IL-2 mRNA 
induction  or regulate  signals  (such  as TCR  signals)  inde- 
pendent of those mediated by CD28. For instance, CTLA-4 
and CD28 may share common signaling pathways and ini- 
tiation of CTLA-4 signaling may antagonize CD28 signal- 
ing  events  by  preventing  the  interaction  of CD28  with 
necessary cytoplasmic signaling molecules, perhaps by alter- 
ing  phosphorylation  events.  As  an  example,  it  has  been 
shown that both CD28 and CTLA-4 can bind and activate 
PI-3 kinase (40).  However, CTLA-4 hgation may regulate 
PI-3  kinase  activity.  Alternatively,  CTLA-4  cross-linking 
may activate biochemical pathways that  antagonize signals 
initiated by CD28. CD28 has been shown to regulate IL-2 
at the level of IL-2 gene transcription and mRNA stability 
(41-43). Thus, CTLA-4 signals may regulate IL-2 secretion 
by inhibiting  the  induction  of specific  IL-2  transcription 
factors or affect posttranscriptional stability of IL-2 mRNA. 
Finally, it is difficult to determine from the present stud- 
ies how early CTLA-4 acts in blocking T  cell  activation. 
The present findings suggest that  CTLA-4 downregulates 
naive T  cell activation subsequent to CD28 signaling. Un- 
hke  CD28,  little  CTLA-4  is  detectable  on  naive  T  cells. 
Rather,  CTLA-4  is  upregulated  after  T  cell  activation, 
peaking on the cell surface at 48-72 h. Moreover, CTLA-4 
upregulation is CD28-dependent,  as blockade of CD28 li- 
gation inhibits CTLA-4 induction  while  increased signal- 
ing  through  CD28  increases  CTLA-4  expression  on  the 
cell surface (data not shown).  Thus,  CTLA-4 seems hkely 
to function subsequently to initial T  cell activation events. 
However,  it  remains  possible  that  some  T  cells,  perhaps 
memory or recently activated T  cells, may express low lev- 
els  of CTLA-4  on the  cell surface.  Under  these  circum- 
stances CTLA-4 engagement may block the initiation of T 
cell  activation.  In  either  case,  it  has  become increasingly 
clear that CTLA-4 serves a role as a major repressor of the 
immune response.  Future studies will focus on manipulat- 
ing this downregulatory function to either enhance subop- 
timal immune responses in cancer and infectious disease  or 
block activated T  cells in transplantation and autoimmunity. 
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